Last reviewed · How we verify
Phentermine and Topiramate — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Phentermine and Topiramate (Phentermine and Topiramate) — VIVUS LLC. Phentermine and topiramate reduce appetite and food consumption through different mechanisms involving catecholamine release and neurotransmitter modulation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Phentermine and Topiramate TARGET | Phentermine and Topiramate | VIVUS LLC | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Phentermine and Topiramate CI watch — RSS
- Phentermine and Topiramate CI watch — Atom
- Phentermine and Topiramate CI watch — JSON
- Phentermine and Topiramate alone — RSS
Cite this brief
Drug Landscape (2026). Phentermine and Topiramate — Competitive Intelligence Brief. https://druglandscape.com/ci/phentermine-and-topiramate. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab